The COmPLETE Study

Heart Failure Clinical Trial

— COmPLETE  

Official title:

Functional Aging in Health and Heart Failure: The COmPLETE Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03986892
• Other study ID #: 182815
• Status: Completed
• Start date: January 3, 2018
• Est. completion date: January 31, 2020

Study information

• Verified date: April 2020
• Source: University of Basel
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The project is designed as a large scale, cross-sectional study. This research seeks to identify physical fitness and cardiovascular parameters that best resemble underlying cardiovascular risk with age. Further, it will examine which physical fitness markers are impaired most in heart failure.

Description:

Cardiovascular (CV) diseases including heart failure are the leading causes of morbidity, with age being the primary risk factor. The combination of age-related organic functional impairment and reduced physical fitness can drastically impact an individual's healthspan. One's lifespan can potentially be prolonged by the preservation or improvement of physical fitness. However, it remains unclear as to which biomarkers are most suitable for distinguishing between healthy aging and the impaired organ function associated with heart failure. Therefore, a comprehensive assessment of the components of physical fitness and CV function will be performed to identify the most important factors contributing to aging in relation to both health and disease.

This cross-sectional investigation will consist of two parts: the COmPLETE-Health (C-Health) and COmPLETE-Heart (C-Heart) studies. C-Health will examine the aging trajectories of physical fitness components and CV properties in a healthy population sample aged between 20 and 100 years (n = 490). Separately, C-Heart will assess the same markers in patients at different stages of chronic heart failure (n = 80). The primary outcome to determine the difference between C-Health and C-Heart will be cardiorespiratory fitness as measured by cardiopulmonary exercise testing on a bicycle ergometer. Secondary outcomes will include walking speed, balance, isometric strength, peak power, and handgrip strength. Physical activity as a behavioural component will be assessed objectively via accelerometry. Further, CV assessments will include pulse wave velocity; retinal, arterial, and venous diameters; brachial and retinal arterial endothelial function; carotid intima-media thickness; and systolic and diastolic function. The health distances for C-Health and C-Heart will be calculated using the methodology based on statistical (Mahalanobis) distance applied to measurements of quantitative biomarkers.

This research seeks to identify physical fitness and CV biomarkers that best resemble underlying CV risk with age. Further, it will examine which physical fitness markers are impaired most in heart failure. The presented integrative approach could define new recommendations for diagnostic guidance in aging. Ultimately, this study is expected to offer a better understanding of which functional characteristics should be specifically targeted in primary and secondary prevention to achieve an optimal healthspan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 678
• Est. completion date: January 31, 2020
• Est. primary completion date: December 20, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 100 Years

Eligibility

Inclusion Criteria

C-Health:

• Healthy men and women aged 20-100 years

• Body mass index < 30 kg/m2

• Nonsmoker

C-Heart:

• Stable CHF (treated patient with symptoms and signs that have remained generally unchanged for at least one month) characterized according to the European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure [82], as follows:

1. HFrEF (LVEF < 40%)

2. HFmHF (LVEF 40-49%)

3. HFpEF (LVEF = 50%) and NT-proBNP > 125 pg/mL and structural or functional changes in echocardiography in no. 2 or 3.

Exclusion criteria

C-Health:

• Age younger than 20 years; manifest exercise limiting chronic disease (e.g., myocardial infarction; stroke; heart failure; lower-extremity artery disease; cancer with general symptoms; diabetes; clinically apparent renal failure; severe liver disease; chronic bronchitis GOLD stages II to IV; osteoporosis), women with known pregnancy or breastfeeding; drug or alcohol abuse; hypertonic blood pressure of less than 160/100 mmHg; compromising orthopaedic problems; Alzheimer's disease or any other form of dementia; inability to follow the procedures of the study (e.g., due to language problems, psychological disorders, dementia of the participant); diseases regarded as an absolute contraindication for maximal exertion; and current or past smoking status.

C-Heart:

• Age younger than 20 years; women with known pregnancy or breastfeeding; drug or alcohol abuse; inability to follow the study procedures (e.g., due to language problems, psychological disorders, etc.); unstable angina pectoris; uncontrolled brady- or tachyarrythmia; paroxysmal atrial fibrillation; severe uncorrected valvular disease; acute myocardial infarction or coronary syndrome; transient ischemic attack or stroke occurring less than three months prior; clinically significant concomitant disease states (e.g. uncontrolled hypertonic blood pressure); clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin and/or cervical intraepithelial neoplasia; currently receiving systemic chemotherapy and/or radiotherapy; significant musculoskeletal disease other than that associated with heart failure limiting exercise tolerance; active infection; immunosuppressive medical therapy; life-expectancy of less than six months; and prevalence of a disease regarded as an absolute contraindication for maximal exertion.

Related Conditions & MeSH terms

• Aging
• Heart Failure

Intervention

Behavioral:
• Physical Activity
Physical Activity

Locations

Country	Name	City	State
Switzerland	Department for Sport, Exercise and Health, Section Sports and Exercise Medicine, University of Basel	Basel

Sponsors (1)

Lead Sponsor	Collaborator
Arno Schmidt-Trucksäss

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiorespiratroy Fitness	Maximal Oxygen uptake measured by cardiopulmonary exercise testing (VO2peak) in L/min	3 hours after inclusion in study
Primary	Ventilatory Efficiency	VE/VCO2 measured by cardiopulmonary exercise testing ((L/min)/(L/min))	3 hours after inclusion in study
Primary	Oxygen Uptake Efficiency	The Oxygen Uptake Efficiency Slope is defined as the regression slope 'a' in V?O2 = a × log VE +b measured by cardiopulmonary exercise testing.	3 hours after inclusion in study
Primary	Gait speed	Gait speed measured by an inertial sensor system in m/s.	1.5 hours after inclusion in study
Primary	Standing balance	The cumulative sway path (cm) serves as a measure of postural control.	2.5 hours after inclusion in study
Primary	Hand grip strength	Measured by a handheld dynamometer. Maximal achieved grip strength (kg) is recorded.	2.5 hours after inclusion in study
Primary	Power of leg muscles	Peak power measured by countermovement jump performed on a force plate. Reported in N/kg	2.5 hours after inclusion in study
Primary	Arterial stiffness	Meausred by an noninvasive vascular screening system. Reported as brachial-ankle pulse wave velocity (baPWV).	0.5 hours after inclusion in study
Primary	Endothelial function	Meausred as flow mediated dilation (FMD) by ultrasound reported as %.	1 hours after inclusion in study
Primary	Left ventricular ejection fraction	Meausred by echocardiography reported as %.	1 hour after inclusion in study
Primary	Carotid-intima-media thickness	Carotid intima-media thickness (mm) is measured by 2D ultrasound instrument.	1 hour after inclusion in study
Primary	Retinal arterial and venous diameters	Measured by static retinal vessel analysis. Diameters will be averaged to central retinal arteriolar and venular equivalents (CRAE and CRVE) and the arteriolar-to-venular diameter ratio will be calculated from the CRAE and CRVE.	7-30 days after inclusion in study
Primary	Retinal endothelial function	Measured by dynamic retinal vessel analysis reported as %.	7-30 days after inclusion in study